Theralase Technologies Inc. (TLT.V)

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it provides controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada.